Table 2 Clinical nodal staging scores for selected values of the number of LNs examined in the development cohort of 4770 patients who underwent radical prostatectomy and bilateral pelvic lymph node dissection for localised prostate cancer
From: Clinical nodal staging scores for prostate cancer: a proposal for preoperative risk assessment
No. of examined LNs | 1 | 3 | 5 | 8 | 10 | 12 | 15 | 20 |
|---|---|---|---|---|---|---|---|---|
Clinical T stage | ||||||||
T1 | 92.4 | 94.4 | 95.9 | 97.3 | 97.9 | 98.4 | 98.9 | 99.3 |
T2 | 80.7 | 85.4 | 88.9 | 92.5 | 94.2 | 96.4 | 96.8 | 98.1 |
T3 | — | — | 80.3 | 86.3 | 89.2 | 91.4 | 93.8 | 96.3 |
Bx Gleason score | ||||||||
6 | 95.5 | 96.8 | 97.6 | 98.5 | 98.8 | 99.0 | 99.4 | 99.6 |
7 | 88.0 | 91.2 | 93.4 | 95.6 | 96.6 | 97.4 | 98.1 | 98.9 |
8–10 | 74.8 | 80.6 | 85.0 | 89.8 | 92.0 | 93.7 | 95.5 | 97.3 |
Preoperative PSA (ng ml−1) | ||||||||
<10 | 91.9 | 94.1 | 95.6 | 97.1 | 97.8 | 98.3 | 98.8 | 99.3 |
⩾10 | 81.5 | 86.1 | 89.4 | 92.9 | 94.5 | 95.7 | 96.9 | 98.2 |
Risk stratification | ||||||||
Low risk | 96.1 | 97.3 | 98.1 | 98.8 | 99.1 | 99.4 | 99.6 | 99.8 |
Intermediate risk | 89.6 | 92.6 | 94.7 | 96.7 | 97.6 | 98.2 | 98.8 | 99.2 |
High risk | 74.3 | 80.8 | 85.7 | 90.8 | 93.1 | 94.7 | 96.5 | 98.1 |
